TP53 and B-cell chronic lymphocytic leukemia: Our findings indicate that in CLL cells, the combination of PRIMA-1Met with SAS significantly decreases antioxidant capacity and increases ROS production, leading to a synergistic reduction in cell survival in both wt and mutant p53 carrying cells.